免疫治疗时代及未来的头颈癌挽救性手术:综述
本综述探讨头颈鳞状细胞癌(HNSCC)挽救性手术在免疫治疗时代的演变,评估当前证据与临床意义。挽救性手术适应证尚不统一,报告的5年生存率范围为10%至61%。早期单机构试验提示免疫治疗联合挽救性手术可能改善生存、降低复发,但整合仍处早期阶段。
要点
- 挽救性手术是局部区域复发HNSCC的重要治疗选择,但适应证不统一。
- 报告5年生存率范围为10%至61%,提示患者选择差异大。
- 早期单机构试验提示免疫联合挽救性手术可能改善生存与降低复发。
核心结论
- 免疫治疗进展及未来临床试验有望改善HNSCC挽救性手术的患者选择并优化手术结局。
研究设计与样本
- 本文为综述,评估免疫治疗时代HNSCC挽救性手术的当前证据、临床意义与未来方向。
主要发现
- 挽救性手术适应证仍多样且缺乏标准化,报告5年生存率范围为10%至61%。
- 早期单机构试验提示免疫治疗联合挽救性手术可能提高复发或持续HNSCC患者的生存、降低复发率并改善其他结局。
关键数值与推荐
- 报告5年生存率范围为10%至61%。
临床怎么用
- 在局部区域复发HNSCC中,挽救性手术仍是重要治疗选择,但需个体化评估适应证。
- 免疫治疗联合挽救性手术的整合尚处早期,应关注临床试验证据。
局限性
- 挽救性手术适应证不统一且缺乏标准化。
- 免疫治疗整合于HNSCC手术方案仍处早期阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Head and neck squamous cell carcinoma (HNSCC) is a challenging malignant condition associated with significant morbidity and mortality. Salvage surgery, in addition to other available treatment modalities, constitutes an important therapeutic intervention for locoregionally recurrent HNSCC, offering the potential for improved locoregional control and survival outcomes. However, the indications for salvage surgery remain diverse and poorly standardized, with reported 5-year survival outcome rates ranging from 10% to 61%. In recent years, the incorporation of immunotherapy into the management of recurrent and locally advanced HNSCC has shown promising potential. Although preoperative immunotherapy has resulted in improved outcomes in other malignant neoplasms, such as non-small cell lung cancer, its integration into HNSCC surgical protocols whether in the primary or salvage setting is still in its early stages. Early single-institution trials suggest combining immunotherapy with salvage surgery may enhance survival, reduce recurrence rates, and improve other outcomes for patients with recurrent or persistent HNSCC. OBSERVATIONS: This review explores the evolving landscape of HNSCC salvage surgery in the era of immunotherapy by assessing current evidence, clinical implications, and future directions for this integrated approach. CONCLUSIONS AND RELEVANCE: Advances in immunotherapy and the development of future clinical trials incorporating immunotherapy in the HNSCC salvage setting have the potential to enhance patient selection and optimize surgical outcomes.
引用
- Saba NF, Zalaquett NG, Rashid S, et al. Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond: A Review. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 41037305. doi:10.1001/jamaoto.2025.3204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。